From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
Anti-Mouse TNFR2 Antibody (TR75-54.7) is an anti-mouse TNFR2 IgG monoclonal antibody. Anti-Mouse TNFR2 Antibody (TR75-54.7) can reduce white blood cell count (WBC) and decrease the expression of some pro-inflammatory cytokines such as CCL2 and CXCL5. Anti-Mouse TNFR2 Antibody (TR75-54.7) can be used for research on inflammation conditions and cancer such as breast cancer .
Balinatunfib (SAR-441566) is an orally active inhibitor of TNFR1 signaling. By binding to the central pocket of the soluble TNFα (sTNFα) trimer, Balinatunfib stabilizes an asymmetric conformation, blocking its binding to TNFR1 (without affecting TNFR2) and thus inhibiting downstream pathways. Balinatunfib has anti-inflammatory activity, and can be used in the study of autoimmune diseases .
BI-1808 is a human IgG1 monoclonal antibody that targets TNFR2by blocking interaction of TNFR2 with ligand TNF-α, confers FcγR-dependent depletion of Treg and mediates expansion of intratumoral CD8 + T cells .
Infliximab (Avakine) is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α. Infliximab prevents the interaction of TNF-α with TNF-α receptor (TNFR1 and TNFR2). Infliximab has the potential for autoimmune, chronic inflammatory diseases and diabetic neuropathy research .
TNFRSF1A Human Pre-designed siRNA Set A contains three designed siRNAs for TNFRSF1A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Tnfrsf1a Mouse Pre-designed siRNA Set A contains three designed siRNAs for Tnfrsf1a gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
MN-25 (compound 4a) is an orally active indolpyridone that serves as a novel cannabinoid ligand. MN-25 has Ki of 245 nM and 11 nM for CB1 and CB2. MN-25 has CB2 agonist activity and inhibits TNF-R release in human peripheral blood mononuclear cells in vitro with an IC50 of 33 μM. MN-25 shows efficacy in a mouse acute inflammation model at oral doses up to 50 mg/kg >[1].
Atrosimab (ATM-001) is a Fv-Fc1κ fusion protein with strong binding to human TNFR1 with an EC50 value of 0.37 nM. Atrosimab potently inhibits TNF-induced activation of TNFR1. Atrosimab has the potential for the study of chronic inflammatory diseases .
Infliximab (Anti-TNF-α) (Avakine (Anti-TNF-α)) is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α. Infliximab (Anti-TNF-α) prevents the interaction of TNF-α with TNF-α receptor (TNFR1 and TNFR2). Infliximab (Anti-TNF-α) has the potential for autoimmune, chronic inflammatory diseases and diabetic neuropathy research .
Ragifilimab (INCAGN-1876) is an agonist monoclonal antibody targeting the glucocorticoid-induced TNFR-related protein (GITR). Ragifilimab can be used for advanced or metastatic solid tumors research .
Resatorvid (TAK-242) is a selective Toll-like receptor 4 (TLR4) inhibitor. Resatorvid inhibits NO, TNF-α and IL-6 production with IC50s of 1.8 nM, 1.9 nM and 1.3 nM, respectively. Resatorvid downregulates expression of TLR4 downstream signaling molecules MyD88 and TRIF. Resatorvid inhibits autophagy and plays pivotal role in various inflammatory diseases .
SIM-0235 is humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets and inhibits TNFR2, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) [1].
TNF-α (31-45), human is a potent NF-kB pathway activator. TNF-αis a proinflammatory cytokine that induces necrosis or apoptosis. TNF alpha stimulates NF-κB pathway via TNFR2 promotes cancer growth, invasion, and metastasis .
SPD304 is a selective TNF-α inhibitor, which promotes dissociation of TNF trimers and therefore blocks the interaction of TNF and its receptor. SPD304 has an IC50 of 22 μM for inhibiting in vitro TNF receptor 1 (TNFR1) binding to TNF-α .
SPD304 dihydrochloride is a selective TNF-α inhibitor, which promotes dissociation of TNF trimers and therefore blocks the interaction of TNF and its receptor. SPD304 has an IC50 of 22 μM for inhibiting in vitro TNF receptor 1 (TNFR1) binding to TNF-α .
TNF-α (31-45), human TFA is a potent NF-kB pathway activator. TNF-αis a proinflammatory cytokine that induces necrosis or apoptosis. TNF alpha stimulates NF-κB pathway via TNFR2 promotes cancer growth, invasion, and metastasis .
Nafamostat, an anticoagulant, is a synthetic serine protease inhibitor. Nafamostat has anticancer and antivirus effect. Nafamostat induce apoptosis by up-regulating the expression of tumor necrosis factor receptor-1(TNFR1). Nafamostat can be used in the development of the pathological thickening of the arterial wall .
Nafamostat hydrochloride, an anticoagulant, is a synthetic serine protease inhibitor. Nafamostat hydrochloride has anticancer and antivirus effect. Nafamostat hydrochloride induces apoptosis by up-regulating the expression of tumor necrosis factor receptor-1(TNFR1). Nafamostat hydrochloride can be used in the development of the pathological thickening of the arterial wall .
Benpyrine is a highly specific and orally active TNF-α inhibitor with a KD value of 82.1 μM. Benpyrine tightly binds to TNF-α and blocks its interaction with TNFR1, with an IC50 value of 0.109 µM. Benpyrine has the potential for TNF-α mediated inflammatory and autoimmune disease research .
Nafamostat mesylate (FUT-175), an anticoagulant, is a synthetic serine protease inhibitor. Nafamostat mesylate has anticancer and antivirus effect. Nafamostat mesylate induce apoptosis by up-regulating the expression of tumor necrosis factor receptor-1(TNFR1). Nafamostat mesylate can be used in the development of the pathological thickening of the arterial wall .
TNF-α-IN-2 is a potent and orally active inhibitor of tumor necrosis factor alpha (TNFα), with an IC50 of 25 nM in the HTRF assay. TNF-α-IN-2 distorts the TNFα trimer upon binding, leading to aberrant signaling when the trimer binds to TNFR1. TNF-α-IN-2 can be used for the research of rheumatoid arthritis .
(R)-Benpyrine is the isomer of Benpyrine (HY-133807), and can be used as an experimental control. Benpyrine is a highly specific and orally active TNF-α inhibitor with a KD value of 82.1 μM. Benpyrine tightly binds to TNF-α and blocks its interaction with TNFR1, with an IC50 value of 0.109 μM. Benpyrine has the potential for TNF-α mediated inflammatory and autoimmune disease research .
Atrosab is a humanized IgG1 antagonistic anti-TNFR1 antibody. Atrosab inhibits TNF-mediated Apoptosis induction and IL-6 and IL-8 production. Atrosab reduces neurological deficits. Atrosab can be used for research of inflammatory disease. The recommend isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
Nafamostat (mesylate) (Standard) is the analytical standard of Nafamostat (mesylate). This product is intended for research and analytical applications. Nafamostat mesylate (FUT-175), an anticoagulant, is a synthetic serine protease inhibitor. Nafamostat mesylate has anticancer and antivirus effect. Nafamostat mesylate induce apoptosis by up-regulating the expression of tumor necrosis factor receptor-1 (TNFR1). Nafamostat mesylate can be used in the development of the pathological thickening of the arterial wall .
Δ7(Z)-C14-HSL (Compound 12) is an immunosuppressive agent that can inhibit the proliferation of mouse splenic cells with an IC50 of 17 μM. Δ7(Z)-C14-HSL can be used for further studying its potential as a molecular mechanism in TNF-R-driven immune diseases, especially autoimmune diseases such as psoriasis, rheumatoid arthritis, and type 1 diabetes .
Azadirachtin is an oral active triterpenoid compound with anticancer, antimalarial, anti-inflammatory, and insecticidal activities. Azadirachtin induces cell apoptosis through the mitochondrial pathway (by inhibiting Bcl-2/Bax ratio or activating Apaf-1 and caspase-3) or through death receptors (by inhibiting TNFR activation). Additionally, Azadirachtin exerts its anti-inflammatory effects by inhibiting NF-кB signaling pathway activation, and it exhibits insecticidal activity by inducing apoptosis in insect cells .
R1-ICR-5 is a selective PROTAC degrader that targets serine/threonine-protein kinase 1 (RIPK1). R1-ICR-5 mediates the degradation of RIPK1 through VHL, thereby deregulating the TNFR1 and TLR3/4 signaling hubs, enhancing the output of NF-κB, MAPK, and IFN signaling, and simultaneously promoting the activation of RIPK3 and the induction of necroptosis. R1-ICR-5 is promising for research of cancers and inflammatory diseases. (Pink: PK68 (HY-128348); Black: linker (HY-W012241); Blue: (S,R,S)-AHPC (HY-125845) .
TNF-α (31-45), human is a potent NF-kB pathway activator. TNF-αis a proinflammatory cytokine that induces necrosis or apoptosis. TNF alpha stimulates NF-κB pathway via TNFR2 promotes cancer growth, invasion, and metastasis .
TNF-α (31-45), human TFA is a potent NF-kB pathway activator. TNF-αis a proinflammatory cytokine that induces necrosis or apoptosis. TNF alpha stimulates NF-κB pathway via TNFR2 promotes cancer growth, invasion, and metastasis .
Anti-Mouse TNFR2 Antibody (TR75-54.7) is an anti-mouse TNFR2 IgG monoclonal antibody. Anti-Mouse TNFR2 Antibody (TR75-54.7) can reduce white blood cell count (WBC) and decrease the expression of some pro-inflammatory cytokines such as CCL2 and CXCL5. Anti-Mouse TNFR2 Antibody (TR75-54.7) can be used for research on inflammation conditions and cancer such as breast cancer .
BI-1808 is a human IgG1 monoclonal antibody that targets TNFR2by blocking interaction of TNFR2 with ligand TNF-α, confers FcγR-dependent depletion of Treg and mediates expansion of intratumoral CD8 + T cells .
Infliximab (Avakine) is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α. Infliximab prevents the interaction of TNF-α with TNF-α receptor (TNFR1 and TNFR2). Infliximab has the potential for autoimmune, chronic inflammatory diseases and diabetic neuropathy research .
Atrosimab (ATM-001) is a Fv-Fc1κ fusion protein with strong binding to human TNFR1 with an EC50 value of 0.37 nM. Atrosimab potently inhibits TNF-induced activation of TNFR1. Atrosimab has the potential for the study of chronic inflammatory diseases .
Infliximab (Anti-TNF-α) (Avakine (Anti-TNF-α)) is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α. Infliximab (Anti-TNF-α) prevents the interaction of TNF-α with TNF-α receptor (TNFR1 and TNFR2). Infliximab (Anti-TNF-α) has the potential for autoimmune, chronic inflammatory diseases and diabetic neuropathy research .
Ragifilimab (INCAGN-1876) is an agonist monoclonal antibody targeting the glucocorticoid-induced TNFR-related protein (GITR). Ragifilimab can be used for advanced or metastatic solid tumors research .
Atrosab is a humanized IgG1 antagonistic anti-TNFR1 antibody. Atrosab inhibits TNF-mediated Apoptosis induction and IL-6 and IL-8 production. Atrosab reduces neurological deficits. Atrosab can be used for research of inflammatory disease. The recommend isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
SIM-0235 is humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets and inhibits TNFR2, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) [1].
Anti-Mouse CD40 Antibody (FGK4.5/FGK45) is a rat-derived IgG2a monoclonal antibody targeting mouse CD40. CD40 is a type I transmembrane glycoprotein that belongs to the tumor necrosis factor receptor (TNFR) superfamily. CD40 can act as a co-stimulatory molecule to activate B cells, dendritic cells, monocytes, and other APCs, promoting anti-tumor T cell responses.
Azadirachtin is an oral active triterpenoid compound with anticancer, antimalarial, anti-inflammatory, and insecticidal activities. Azadirachtin induces cell apoptosis through the mitochondrial pathway (by inhibiting Bcl-2/Bax ratio or activating Apaf-1 and caspase-3) or through death receptors (by inhibiting TNFR activation). Additionally, Azadirachtin exerts its anti-inflammatory effects by inhibiting NF-кB signaling pathway activation, and it exhibits insecticidal activity by inducing apoptosis in insect cells .
The TNFRII protein is a receptor with high affinity for TNFSF2/TNF-α and low affinity for TNFSF1/lymphotoxin-α, and plays a key role in mediating the metabolic effects of TNF-α. The TRAF1/TRAF2 complex recruits BIRC2 and BIRC3 to TNFRSF1B/TNFR2 to regulate the apoptotic pathway. TNFRII Protein, Human (183a.a) is the recombinant human-derived TNFRII protein, expressed by E. coli , with tag free.
TNFRSF1A (TNF RI) protein has a high ability to
bind with tumor necrosis factor-alpha (TNF-α). TNFRSF1A is a STAT3 target gene
that regulates the NF-κB pathway. TNFRSF1A activate NF-κB, mediate apoptosis,
and function as a regulator of inflammation. TNFRSF1A Protein, Human (His) is
expressed by E. coli and has a transmembrane region (I22-T211)
with a 6*His tag at the N-terminus.
The TNFR-1/CD120a protein is a receptor for TNFSF2/TNF-α and TNFSF1/lymphotoxin-α, and initiates caspase-8-mediated apoptosis upon TNF binding. It induces non-cytocidal TNF action, activates acid sphingomyelinase and establishes an antiviral state. TNFR-1/CD120a Protein, Human (HEK293, His) is the recombinant human-derived TNFR-1/CD120a protein, expressed by HEK293 , with C-8*His labeled tag.
The TNFR-1/CD120a protein is a receptor for TNFSF2/TNF-α and TNFSF1/lymphotoxin-α, and initiates caspase-8-mediated apoptosis upon TNF binding. It induces non-cytocidal TNF action, activates acid sphingomyelinase and establishes an antiviral state. TNFR-1/CD120a Protein, Human (HEK293, Fc) is the recombinant human-derived TNFR-1/CD120a protein, expressed by HEK293 , with C-hFc labeled tag.
The TNFRII protein is a receptor with high affinity for TNFSF2/TNF-α and low affinity for TNFSF1/lymphotoxin-α, and plays a key role in mediating the metabolic effects of TNF-α. The TRAF1/TRAF2 complex recruits BIRC2 and BIRC3 to TNFRSF1B/TNFR2 to regulate the apoptotic pathway. TNF RII/TNFRSF1B Protein, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived TNF RII/TNFRSF1B protein, expressed by HEK293 , with C-Avi, C-His labeled tag.
The TNFRII protein is a receptor with high affinity for TNFSF2/TNF-α and low affinity for TNFSF1/lymphotoxin-α, and plays a key role in mediating the metabolic effects of TNF-α. The TRAF1/TRAF2 complex recruits BIRC2 and BIRC3 to TNFRSF1B/TNFR2 to regulate the apoptotic pathway. TNF RII/TNFRSF1B Protein, Human (Biotinylated, HEK293, His) is the recombinant human-derived TNF RII/TNFRSF1B protein, expressed by HEK293 , with C-His labeled tag.
TNFRII (TNFRSF1B) protein has a high ability to bind with tumor necrosis factor-alpha (TNF-α). TNFRII has pro-apoptotic function. TNFRII recruits TRAF2, induces gene expression and intensively crosstalks with TNF-R1. TNFRII selectively enhances the induction of apoptosis by the death receptor TNFRI. TNF RII/TNFRSF1B Protein, Human (235a.a, HEK293, mFc) is expressed by HEK293 and has a transmembrane region (M1-D257) with mFc tag at the C-terminus.
TNFRSF1A Protein exhibits a deficiency in conserved residue(s) crucial for feature annotation propagation. TNFRSF1A Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived TNFRSF1A protein, expressed by HEK293 , with C-His labeled tag.
TNFRII (TNFRSF1B) protein has a high ability to bind with tumor necrosis factor-alpha (TNF-α). TNFRII has pro-apoptotic function. TNFRII recruits TRAF2, induces gene expression and intensively crosstalks with TNF-R1. TNFRII selectively enhances the induction of apoptosis by the death receptor TNFRI. TNF RII/TNFRSF1B Protein, Mouse (HEK293, Fc) is expressed by HEK293 and has a transmembrane region with Fc tag at the C-terminus.
TNFRII (TNFRSF1B) protein has a high ability to bind with tumor necrosis factor-alpha (TNF-α). TNFRII has pro-apoptotic function. TNFRII recruits TRAF2, induces gene expression and intensively crosstalks with TNF-R1. TNFRII selectively enhances the induction of apoptosis by the death receptor TNFRI. TNF RII/TNFRSF1B Protein, Rhesus Macaque (HEK293, His) is expressed by HEK293 and has a transmembrane region (L23-D257) with 6*His tag at the C-terminus.
TNFRII (TNFRSF1B) protein has a high ability to bind with tumor necrosis factor-alpha (TNF-α). TNFRII has pro-apoptotic function. TNFRII recruits TRAF2, induces gene expression and intensively crosstalks with TNF-R1. TNFRII selectively enhances the induction of apoptosis by the death receptor TNFRI. TNF RII/TNFRSF1B Protein, Cynomolgus/Rhesus Macaque (HEK293, Fc) is expressed by HEK293 and has a transmembrane region (M1-D257) with hFc tag at the C-terminus.
TNFRII (TNFRSF1B) protein has a high ability to bind with tumor necrosis factor-alpha (TNF-α). TNFRII has pro-apoptotic function. TNFRII recruits TRAF2, induces gene expression and intensively crosstalks with TNF-R1. TNFRII selectively enhances the induction of apoptosis by the death receptor TNFRI. TNFRII Protein, Human (257a.a, HEK293, His) is expressed by HEK293 and has a transmembrane region (M1-D257) with His tag at the C-terminus.
TNFRSF1A (TNF RI) protein has a high
ability to bind with tumor necrosis factor-alpha (TNF-α). TNFRSF1A is a STAT3
target gene that regulates the NF-κB pathway. TNFRSF1A activate NF-κB, mediate
apoptosis, and function as a regulator of inflammation. TNFRSF1A Protein, Rat
(HEK293, His) is expressed by HEK293 and has a transmembrane region (M1-A211) with
a His tag at the C-terminus.
TNFRSF1A (TNF RI) protein has a high
ability to bind with tumor necrosis factor-alpha (TNF-α). TNFRSF1A is a STAT3
target gene that regulates the NF-κB pathway. TNFRSF1A activate NF-κB, mediate
apoptosis, and function as a regulator of inflammation. TNFRSF1A Protein, Rat
(HEK293, Fc) is expressed by HEK293 and has a transmembrane region with a Fc tag at the C-terminus.
TNFRSF1A (TNF RI) protein has a high
ability to bind with tumor necrosis factor-alpha (TNF-α). TNFRSF1A is a STAT3
target gene that regulates the NF-κB pathway. TNFRSF1A activate NF-κB, mediate
apoptosis, and function as a regulator of inflammation. TNF RI/TNFRSF1A
Protein, Mouse is expressed by E. coli and has a
transmembrane region (I22-A212).
TNFRSF1A (TNF RI) protein has a high ability
to bind with tumor necrosis factor-alpha (TNF-α). TNFRSF1A is a STAT3 target
gene that regulates the NF-κB pathway. TNFRSF1A activate NF-κB, mediate
apoptosis, and function as a regulator of inflammation. TNF RI/TNFRSF1A Protein,
Mouse (HEK293, Fc) is expressed by HEK 293 cells and has a transmembrane region
with a Fc tag at the C-terminus.
TNFRSF1A (TNF RI) protein has a high
ability to bind with tumor necrosis factor-alpha (TNF-α). TNFRSF1A is a STAT3
target gene that regulates the NF-κB pathway. TNFRSF1A activate NF-kappaB,
mediate apoptosis, and function as a regulator of inflammation. TNF RI/TNFRSF1A
Protein, Mouse (HEK293, His) is expressed by HEK 293 cells and has a
transmembrane region with a His tag at the
C-terminus.
TNFRII (TNFRSF1B) protein has a high ability to bind with tumor necrosis factor-alpha (TNF-α). TNFRII has pro-apoptotic function. TNFRII recruits TRAF2, induces gene expression and intensively crosstalks with TNF-R1. TNFRII selectively enhances the induction of apoptosis by the death receptor TNFRI. TNFRII Protein, Human (HEK293, hFc) is expressed by HEK293 and has a transmembrane region (L23-D257) with hFc tag at the C-terminus.
TNFRII (TNFRSF1B) protein has a high ability to bind with tumor necrosis factor-alpha (TNF-α). TNFRII has pro-apoptotic function. TNFRII recruits TRAF2, induces gene expression and intensively crosstalks with TNF-R1. TNFRII selectively enhances the induction of apoptosis by the death receptor TNFRI. TNFRII Protein, Human (174a.a, HEK293, His) is expressed by HEK293 and has a transmembrane region (K288-S461) with 6*His tag at the C-terminus.
TNFRSF3/LTBR Protein, Rat (HEK293, Fc) is a cell surface receptor for apoptotic and cytokine-released lymphotoxins involved in activation of gene transcription programs and cell death, and is important in immune development and host defense. TNFRSF3/LTBR Protein, Rat (HEK293, Fc) is expressed by HEK293 cells with a His tag at the C-terminus.
TNFRSF3/LTBR Protein, Rat (HEK293, His) is a cell surface receptor for apoptotic and cytokine-released lymphotoxins involved in activation of gene transcription programs and cell death, and is important in immune development and host defense. TNFRSF3/LTBR Protein, Rat (HEK293, His) is expressed by HEK293 cells and is a transmembrane protein (M222-W245) with a His tag at the C-terminus.
TNFRSF3/LTBR Protein,Cynomolgus (HEK293, Fc) is a cell surface receptor for apoptotic and cytokine-released lymphotoxins involved in activation of gene transcription programs and cell death, and is important in immune development and host defense. TNFRSF3/LTBR Protein, Cynomolgus (HEK293, Fc) is expressed by HEK293 cells and is a transmembrane protein (M225-W248) with a His tag at the C-terminus.
TNFRSF3/LTBR Protein, Human (HEK293, Fc) is a cell surface receptor for apoptotic and cytokine-released lymphotoxins involved in activation of gene transcription programs and cell death, and is important in immune development and host defense. TNFRSF3/LTBR Protein, Human (HEK293, Fc) is expressed by HEK293 cells and is a transmembrane protein (L228-W248) with a Fc tag at the C-terminus.
TNFRSF3/LTBR Protein, Human (HEK293, His) is a cell surface receptor for apoptotic and cytokine-released lymphotoxins involved in activation of gene transcription programs and cell death, and is important in immune development and host defense. TNFRSF3/LTBR Protein, Human (HEK293, His) is expressed by HEK293 cells and is a transmembrane protein (L228-W248) with a His tag at the C-terminus.
TNFRII (TNFRSF1B) protein has a high ability to bind with tumor necrosis factor-alpha (TNF-α). TNFRII has pro-apoptotic function. TNFRII recruits TRAF2, induces gene expression and intensively crosstalks with TNF-R1. TNFRII selectively enhances the induction of apoptosis by the death receptor TNFRI. TNF RII/TNFRSF1B Protein, Human (183a.a, HEK293, mFc) is expressed by HEK293 and has a transmembrane region (P24-T206) with mFc tag at the C-terminus.
TNFRSF1A (TNF RI) protein has a high
ability to bind with tumor necrosis factor-alpha (TNF-α). TNFRSF1A is a STAT3
target gene that regulates the NF-κB pathway. TNFRSF1A activate NF-κB, mediate
apoptosis, and function as a regulator of inflammation. TNFRSF1A Protein, Human
(CHO) is expressed by CHO and has a transmembrane region (D41-N201) .
TNFR1 associated DEATH domain protein; TNFR1-associated DEATH domain protein; TNFRSF1A associated via death domain; TNFRSF1A-associated via death domain; tradd; TRADD_HUMAN; Tumor necrosis factor receptor type 1 associated DEATH domain protein; Tumor necrosis factor receptor type 1-associated DEATH domain protein
The TRADD protein acts as a linker for TNFRSF1A/TNFR1 and mediates its interaction with FADD. TRADD induces TNF-induced responses: apoptosis and NF-kappa-B activation. TRADD Protein, Human (His) is the recombinant human-derived TRADD protein, expressed by E. coli , with C-6*His labeled tag.
GITR (TNFRSF18) is a member of the TNFR superfamily. GITR promotes T cell activation and proliferation and increases resistance to tumors and viral infections, and exacerbates autoimmune diseases and inflammation processes. GITR Protein, Human (HEK293, hFc) is a recombinant protein with a C-terminal Fc label, It consists of 136 amino acids (Q26-E161) and is produced in HEK293 cells.
GITR (TNFRSF18) is a member of the TNFR superfamily. GITR promotes T cell activation and proliferation and increases resistance to tumors and viral infections, and exacerbates autoimmune diseases and inflammation processes. GITR Protein, Human (T45A, HEK293, mFc) is a recombinant protein with a C-terminal Fc label and T at position 45 is mutated to A. It consists of 136 amino acids (Q26-E161) and is produced in HEK293 cells.
As a chaperone with ATPase activity, TRAP1 protein plays a crucial role in protecting mitochondrial function and polarization, especially downstream of PINK1 and mitochondrial complex I. TRAP1 acts as a negative regulator of mitochondrial respiration, affecting the balance between oxidative phosphorylation and aerobic glycolysis. TRAP1 Protein, Human (GST) is the recombinant human-derived TRAP1 protein, expressed by E. coli , with N-GST labeled tag.
TNF Receptor 2 Antibody is a non-conjugated and Rabbit origined polyclonal antibody about 48 kDa, targeting to TNF Receptor 2. It can be used for WB,IHC-F,IHC-P,ICC/IF,FC,IP assays with tag free, in the background of Human, Mouse, Rat.
AA930854; TNFR1 associated DEATH domain protein; tradd
WB, IHC-P, ICC/IF, IP
Human, Mouse, Rat
TRADD Antibody (YA2276) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA2276), targeting TRADD, with a predicted molecular weight of 34 kDa (observed band size: 34 kDa). TRADD Antibody (YA2276) can be used for WB, IHC-P, ICC/IF, IP experiment in human, mouse, rat background.
NGFR Antibody (YA2774) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA2774), targeting NGFR, with a predicted molecular weight of 45 kDa (observed band size: 75 kDa). NGFR Antibody (YA2774) can be used for WB, IHC-P, ICC/IF, IP experiment in human, mouse, rat background.
TNFRSF1A Antibody (YA3855) is a mouse-derived and non-conjugated IgG1 antibody, targeting to TNFRSF1A. It can be applicated for ICC/IF, FC, ELISA assays, in the background of human.
CD120B Antibody (YA3868) is a mouse-derived and non-conjugated IgG2b antibody, targeting to CD120B. It can be applicated for WB, FC, ELISA assays, in the background of human, mouse.
LTBR Antibody (YA3985) is a mouse-derived and non-conjugated IgG2a antibody, targeting to LTBR. It can be applicated for WB, FC, ELISA assays, in the background of human, mouse.
AIP 1; AIP1; API 2; API2; API2; Apoptosis inhibitor 2; Baculoviral IAP repeat containing 3; Baculoviral IAP repeat containing protein 3; Baculoviral IAP repeat-containing protein 3; BIRC 3; BIRC3; BIRC3; BIRC3_HUMAN; C IAP2; C-IAP2; CIAP 2; CIAP 2; CIAP2; HAIP 1; HAIP1; HAIP1; HIAP 1; HIAP-1; HIAP1; IAP homolog C; IAP-1; Inhibitor of apoptosis protein 1; Inhibitor of apoptosis protein 1; MALT 2; MALT2; Mammalian IAP homolog C; MIHC; MIHC; RING finger protein 49; RNF49; TNFR2 TRAF signaling complex protein 1; TNFR2 TRAF signalling complex protein; TNFR2-TRAF-signaling complex protein 1.
WB
Human, Monkey
cIAP2 Antibody (YA5260) is a mouse-derived and non-conjugated monoclonal antibody, targeting to cIAP2. It can be applicated for WB assays, in the background of human, monkey.
TNFRSF1A Human Pre-designed siRNA Set A contains three designed siRNAs for TNFRSF1A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Tnfrsf1a Mouse Pre-designed siRNA Set A contains three designed siRNAs for Tnfrsf1a gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
Inquiry Online
Your information is safe with us. * Required Fields.
